NO321203B1 - Anvendelse av NF-<Kappa>B-aktiveringsinhibitor for fremstilling av et medikament for behandling av infarkter. - Google Patents
Anvendelse av NF-<Kappa>B-aktiveringsinhibitor for fremstilling av et medikament for behandling av infarkter. Download PDFInfo
- Publication number
- NO321203B1 NO321203B1 NO19993935A NO993935A NO321203B1 NO 321203 B1 NO321203 B1 NO 321203B1 NO 19993935 A NO19993935 A NO 19993935A NO 993935 A NO993935 A NO 993935A NO 321203 B1 NO321203 B1 NO 321203B1
- Authority
- NO
- Norway
- Prior art keywords
- use according
- inhibitors
- proteasome
- inhibitor
- ischemia
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 73
- 206010061216 Infarction Diseases 0.000 title claims description 40
- 230000007574 infarction Effects 0.000 title claims description 40
- 239000003814 drug Substances 0.000 title claims description 27
- 238000011282 treatment Methods 0.000 title claims description 22
- 229940079593 drug Drugs 0.000 title claims description 19
- 230000004913 activation Effects 0.000 title description 11
- 229940079156 Proteasome inhibitor Drugs 0.000 claims abstract description 36
- 239000003207 proteasome inhibitor Substances 0.000 claims abstract description 36
- 208000028867 ischemia Diseases 0.000 claims abstract description 34
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 31
- 230000037361 pathway Effects 0.000 claims abstract description 24
- 102000044159 Ubiquitin Human genes 0.000 claims abstract description 21
- 108090000848 Ubiquitin Proteins 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 230000026731 phosphorylation Effects 0.000 claims description 19
- 238000006366 phosphorylation reaction Methods 0.000 claims description 19
- 206010063837 Reperfusion injury Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical group CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 claims description 12
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 9
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 9
- 206010053648 Vascular occlusion Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 9
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 9
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- -1 peptidyl aldehyde Chemical class 0.000 claims description 5
- 230000002537 thrombolytic effect Effects 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 210000001627 cerebral artery Anatomy 0.000 claims description 4
- 208000037906 ischaemic injury Diseases 0.000 claims description 3
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 230000003501 anti-edematous effect Effects 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000010606 normalization Methods 0.000 claims description 2
- 229920000447 polyanionic polymer Polymers 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 229960000103 thrombolytic agent Drugs 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- 210000004298 cerebral vein Anatomy 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract description 6
- 102000003945 NF-kappa B Human genes 0.000 description 20
- 108010057466 NF-kappa B Proteins 0.000 description 20
- 230000000926 neurological effect Effects 0.000 description 18
- 230000000302 ischemic effect Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 208000006011 Stroke Diseases 0.000 description 15
- 230000010410 reperfusion Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 210000003657 middle cerebral artery Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 8
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 8
- 239000004327 boric acid Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 6
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 125000005620 boronic acid group Chemical class 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical group CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010043647 Thrombotic Stroke Diseases 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000037420 neurological improvement Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229940127337 Glycine Antagonists Drugs 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000006079 Near drowning Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004670 cellular proteolysis Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004171 ischemic cascade Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Organic Insulating Materials (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Artificial Filaments (AREA)
- Transplanting Machines (AREA)
- Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80193697A | 1997-02-15 | 1997-02-15 | |
| US98833997A | 1997-12-03 | 1997-12-03 | |
| PCT/US1998/003077 WO1998035691A1 (en) | 1997-02-15 | 1998-02-17 | Treatment of infarcts through inhibition of nf-kappab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993935D0 NO993935D0 (no) | 1999-08-16 |
| NO993935L NO993935L (no) | 1999-10-04 |
| NO321203B1 true NO321203B1 (no) | 2006-04-03 |
Family
ID=27122399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993935A NO321203B1 (no) | 1997-02-15 | 1999-08-16 | Anvendelse av NF-<Kappa>B-aktiveringsinhibitor for fremstilling av et medikament for behandling av infarkter. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US6271199B2 (https=) |
| EP (1) | EP0979096B1 (https=) |
| JP (1) | JP2001511814A (https=) |
| CN (1) | CN1159061C (https=) |
| AT (1) | ATE240113T1 (https=) |
| AU (1) | AU741802B2 (https=) |
| CA (1) | CA2281224A1 (https=) |
| DE (1) | DE69814618T2 (https=) |
| ES (1) | ES2196547T3 (https=) |
| IL (1) | IL131410A0 (https=) |
| NO (1) | NO321203B1 (https=) |
| NZ (1) | NZ337364A (https=) |
| PT (1) | PT979096E (https=) |
| WO (1) | WO1998035691A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4215219B2 (ja) * | 1997-07-04 | 2009-01-28 | アンジェスＭｇ株式会社 | 脳保護剤 |
| US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
| US20090042807A1 (en) * | 1998-05-20 | 2009-02-12 | Nisar Ahmed Khan | Oligopeptide treatment of ischemia reperfusion injury |
| EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
| US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| EP1223948A2 (en) * | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
| US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| US6713459B1 (en) * | 2000-04-28 | 2004-03-30 | East Tennessee State University | Methods for the prophylactic and therapeutic treatment of cardiac tissue damage |
| CA2429163C (en) * | 2000-11-16 | 2013-02-12 | The Regents Of The University Of California | Marine actinomycete taxon for drug fermentation and product discovery |
| JP4162491B2 (ja) | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
| US7112588B2 (en) | 2001-05-21 | 2006-09-26 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
| US6740674B2 (en) | 2001-05-21 | 2004-05-25 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
| ATE502642T1 (de) * | 2001-10-05 | 2011-04-15 | Zalicus Inc | Kombinationen für die behandlung von immun- entzündlichen erkrankungen |
| ATE517617T1 (de) * | 2001-12-10 | 2011-08-15 | Yansheng Dr Du | Behandlung von parkinson erkrankung mit kape |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
| US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| AU2004253478A1 (en) * | 2003-06-20 | 2005-01-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| ZA200600473B (en) * | 2003-06-20 | 2007-04-25 | Univ California | Salinosporamides and methods for use thereof |
| US7348305B2 (en) | 2003-08-28 | 2008-03-25 | Department Of Veterans Affairs, Rehabilitation | Inhibitor of cardiac tachyarrhythmias |
| US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
| SE0400399D0 (sv) * | 2004-02-20 | 2004-02-20 | Index Pharmaceuticals Ab | Methods and compositions for the treatment or prevention of secondary ischemic injury |
| US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| EP2266988A1 (en) | 2004-04-30 | 2010-12-29 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
| US7425580B2 (en) * | 2004-05-19 | 2008-09-16 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
| EP1771194A2 (en) * | 2004-07-07 | 2007-04-11 | Biodevelops Pharma Entwicklung GmbH | Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface |
| US20060008454A1 (en) * | 2004-07-07 | 2006-01-12 | Dr. Helmut Brunar | Use of a compound for enhancing the expression of membrane proteins on the cell surface |
| US20090191105A1 (en) * | 2004-08-30 | 2009-07-30 | Kazuhiro Tanahashi | Fractionation Apparatus |
| US20060167106A1 (en) * | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
| EP1830838B1 (en) | 2004-12-03 | 2012-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplastic diseases |
| JP4846799B2 (ja) * | 2005-07-05 | 2011-12-28 | バイオテンプト ベー．フェー． | 腫瘍の治療 |
| EP1912664A2 (en) * | 2005-07-06 | 2008-04-23 | Biodevelops Pharma Entwicklung GmbH | Use of a compound for enhancing the expression of membrane proteins on the cell surface |
| WO2007011757A1 (en) * | 2005-07-14 | 2007-01-25 | Myogen, Inc. | Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
| US7691896B2 (en) * | 2005-08-10 | 2010-04-06 | President And Fellows Of Harvard College | Analogs of salinosporamide A |
| EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| ES2293834B1 (es) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
| WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
| DK2120991T3 (da) * | 2007-02-12 | 2014-04-28 | Biotempt Bv | Behandling af traumatisk blødning med korte oligopeptider |
| US20080280968A1 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| WO2009140287A1 (en) | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
| CA2727862C (en) | 2008-06-17 | 2016-04-19 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
| EP2527434B1 (en) | 2010-01-22 | 2017-08-09 | Japan Science and Technology Agency | Probe reagent for measurement of proteolytic activity |
| US8513218B2 (en) | 2010-03-31 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| CN108498532B (zh) | 2012-05-09 | 2021-07-23 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| IN2013MU01431A (https=) | 2013-04-16 | 2015-06-26 | Cipla Ltd | |
| EP3102585B1 (en) | 2014-02-03 | 2021-05-19 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
| TN2016000492A1 (en) | 2014-05-20 | 2018-04-04 | Millennium Pharm Inc | Boron-containing proteasome inhibitors for use after primary cancer therapy. |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| JP2018510859A (ja) | 2015-03-17 | 2018-04-19 | レオン−ナノドラッグズ ゲーエムベーハー | 安定化されたボロン酸化合物を含むナノ粒子 |
| US11897969B2 (en) | 2017-10-26 | 2024-02-13 | The Regents Of The University Of California | Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661270B2 (en) | 1990-03-05 | 1995-07-20 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| EP0824918B1 (en) * | 1995-05-12 | 2007-03-28 | AnGes MG, Inc. | REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB |
| US5942494A (en) | 1995-10-06 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70) |
| JP2000510328A (ja) | 1996-03-19 | 2000-08-15 | プロスクリプト・インコーポレイテッド | ＩкＢαを部位特異的にリン酸化し得るキナーゼ |
| US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
-
1998
- 1998-02-17 US US09/285,170 patent/US6271199B2/en not_active Expired - Lifetime
- 1998-02-17 AU AU61719/98A patent/AU741802B2/en not_active Ceased
- 1998-02-17 NZ NZ337364A patent/NZ337364A/en unknown
- 1998-02-17 PT PT98906511T patent/PT979096E/pt unknown
- 1998-02-17 DE DE69814618T patent/DE69814618T2/de not_active Expired - Lifetime
- 1998-02-17 WO PCT/US1998/003077 patent/WO1998035691A1/en not_active Ceased
- 1998-02-17 CN CNB988033968A patent/CN1159061C/zh not_active Expired - Fee Related
- 1998-02-17 AT AT98906511T patent/ATE240113T1/de not_active IP Right Cessation
- 1998-02-17 EP EP98906511A patent/EP0979096B1/en not_active Expired - Lifetime
- 1998-02-17 JP JP53600398A patent/JP2001511814A/ja not_active Ceased
- 1998-02-17 IL IL13141098A patent/IL131410A0/xx not_active IP Right Cessation
- 1998-02-17 CA CA002281224A patent/CA2281224A1/en not_active Abandoned
- 1998-02-17 ES ES98906511T patent/ES2196547T3/es not_active Expired - Lifetime
-
1999
- 1999-08-16 NO NO19993935A patent/NO321203B1/no unknown
-
2001
- 2001-07-30 US US09/919,116 patent/US20010053760A1/en not_active Abandoned
-
2002
- 2002-04-08 US US10/118,526 patent/US20030069189A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2281224A1 (en) | 1998-08-20 |
| US20030069189A1 (en) | 2003-04-10 |
| AU741802B2 (en) | 2001-12-13 |
| ES2196547T3 (es) | 2003-12-16 |
| US20010053760A1 (en) | 2001-12-20 |
| PT979096E (pt) | 2003-09-30 |
| NO993935L (no) | 1999-10-04 |
| EP0979096B1 (en) | 2003-05-14 |
| NO993935D0 (no) | 1999-08-16 |
| ATE240113T1 (de) | 2003-05-15 |
| US20010002391A1 (en) | 2001-05-31 |
| CN1250376A (zh) | 2000-04-12 |
| NZ337364A (en) | 2001-06-29 |
| HK1025266A1 (en) | 2000-11-10 |
| US6271199B2 (en) | 2001-08-07 |
| DE69814618D1 (de) | 2003-06-18 |
| WO1998035691A1 (en) | 1998-08-20 |
| AU6171998A (en) | 1998-09-08 |
| DE69814618T2 (de) | 2004-03-25 |
| IL131410A0 (en) | 2001-01-28 |
| CN1159061C (zh) | 2004-07-28 |
| JP2001511814A (ja) | 2001-08-14 |
| EP0979096A1 (en) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321203B1 (no) | Anvendelse av NF-<Kappa>B-aktiveringsinhibitor for fremstilling av et medikament for behandling av infarkter. | |
| WO1998035691A9 (en) | Treatment of infarcts through inhibition of nf-kappab | |
| Bystryn et al. | The adjuvant therapy of pemphigus: an update | |
| McDonald et al. | Liver disease after human marrow transplantation | |
| Sommer et al. | Cyclosporine-associated renal arteriopathy resulting in loss of allograft function | |
| Shihab et al. | Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-β1 in chronic cyclosporine nephrotoxicity | |
| Xu et al. | Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy: an overview of pathophysiology, pharmacological targets and candidate drugs focusing on excitotoxicity and free radical | |
| Keown et al. | Effect of cyclosporine on the kidney | |
| Weller et al. | Glucocorticoids and immunosup pressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles | |
| Ginès et al. | Good news for hepatorenal syndrome | |
| JP2005516050A (ja) | 急性心筋梗塞のための複合治療 | |
| WO2012061505A1 (en) | Methods and compositions for prevention and treatment of cardiac hypertrophy | |
| Donnez et al. | Laparoscopic treatment of ampullary tubal pregnancy | |
| CA2111644A1 (en) | Use of thrombin inhibitors for the inhibition of ocular fibrin formation | |
| Bergamaschini et al. | Recent advances in the use of C1 inhibitor as a therapeutic agent | |
| MXPA99007509A (en) | Treatment of infarcts through inhibition of nf-kappab | |
| HK1025266B (en) | Treatment of infarcts through inhibition of nf-kappab | |
| JP4737686B2 (ja) | 新しい医薬 | |
| Bates | Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes | |
| Di Tano et al. | Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. | |
| HK1026640A (en) | Treatment of infarcts through inhibition of nf-kappab | |
| WO2007049468A1 (ja) | 脳梗塞抑制剤 | |
| JP2005500251A (ja) | 洞様毛細血管閉塞症候群および放射線療法誘発性肝疾患を予防および処置するための組成物および方法 | |
| Session | Infarct-related artery patency and long-term effects on left ventricular remodelling | |
| Flier et al. | Anti-inflammatory adjuvant agents in bacterial meningitis |